Table 5 The association between grade 3–4 fluoropyrimidines-related adverse events (FrAEs) and TYMS genotypes.

From: The prevalence and clinical relevance of 2R/2R TYMS genotype in patients with gastrointestinal malignancies treated with fluoropyrimidine-based chemotherapy regimens

Patients

Grade 3–4 FrAEs, N [%]

p

Patients with genotypes that predict increased TS expression (N = 55)

12 [22%]

p = 0.0219

Patients with genotypes that predict decreased TS expression (N = 71)

30 [42%]

 

Patients with genotypes that predict increased TS expression (N = 55)

12 [22%]

p = 0.0039

Patients with 2R/2R genotype that predict decreased TS expression (N = 31)

17 [55%]

 

Patients with genotypes that predict increased TS expression (N = 55)

12 [22%]

p = 0.1108

Patients with 2R/3RC and 3RC/3RC TYMS genotypes that predict decreased TS expression (N = 40)

15 [38%]

 
  1. Statistical analysis was performed using Fisher’s exact test.
Back to article page